Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis

A new nanocarrier is developed for the passage of gatifloxacin through the blood–brain barrier to treat central nervous system tuberculosis. Gatifloxacin nanoparticles were prepared by nanoprecipitation using poly(lactic-co-glycolic acid) (PLGA) 502 and polysorbate 80 or Labrafil as surface modifier...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcianes, Patricia, Negro, Sofia, García-García, Luis, Montejo, Consuelo, Barcia, Emilia, Fernández-Carballido, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357078/
https://www.ncbi.nlm.nih.gov/pubmed/28331318
http://dx.doi.org/10.2147/IJN.S130908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357078/
https://www.ncbi.nlm.nih.gov/pubmed/28331318
http://dx.doi.org/10.2147/IJN.S130908

Ejemplares similares